Article references (17 references )


  1. Fyfe TM, Ritchey MJ, Taruc C, Crompton D, Galliford B, Perrin R. Appropriate provision of anti-D prophylaxis to RhD negative pregnant women: a scoping review. BMC Pregnancy Childbirth. 2014; 14: 411. PubMed | Google Scholar

  2. Urbaniak SJ, Greiss MA. RhD haemolytic disease of the fetus and the newborn. Blood Rev. 2000; 14(1): 44-61. PubMed | Google Scholar

  3. Fung Kee Fung K, Eason E, Crane J, Armson A et al. Prevention of Rh alloimmunization. J Obstet Gynaecol Can. 2003; 25(9): 765-773. PubMed | Google Scholar

  4. Fatih Demircioglu, Sule Çaglayan Sözmen, Sebnem Yilmaz, Hale Ören, Nur Arslan, Abdullah Kumra et al. Severe iron overload and hyporegenerative anemia in a case with rhesus hemolytic disease: therapeutic approach to rare complications. Turkish J Haematol. 2010; 27(3): 204-208. PubMed | Google Scholar

  5. Pessler F, Hart D. Hyporegenerative anemia associated with Rh hemolytic disease: treatment failure of recombinant erythropoietin. J Pediatr Hematol Oncol. 2002; 24(8): 689-693. PubMed | Google Scholar

  6. Jain A, Poddar U, Elhence P, Tripathi A, Shava U, Yachha SK. Cholestasis in a neonate with ABO haemolytic disease of newborn following transfusion of ABO group-specific red cells compatible with neonatal serum: inspissated bile syndrome. Blood Transfus. 2014; 12(4): 621-623. PubMed | Google Scholar

  7. Ree IMC, Smits-Wintjens VEHJ, van der Bom JG, van Klink JMM, Oepkes D, Lopriore E. Neonatal management and outcome in alloimmune hemolytic disease. Expert Rev Hematol. 2017; 10(7): 607-616. PubMed | Google Scholar

  8. Al-Alaiyan S, Al Omran A. Late hyporegenerative anemia in neonates with rhesus hemolytic disease. J Perinat Med. 1999; 27(2): 112-115. PubMed | Google Scholar

  9. Strand C, Polesky HF. Delayed anemia in erythroblastosis fetalis. Minn Med. 1972; 55(5): 439-441. PubMed | Google Scholar

  10. Nicaise C, Gire C, Casha P, d'Ercole C, Chau C, Palix C. Erythropoietin as Treatment for Late Hyporegenerative Anemia in Neonates with Rh Hemolytic Disease after in utero Exchange Transfusion. Fetal Diagn Ther. 2002; 17(1): 22-24. PubMed | Google Scholar

  11. Maier RF, Obladen M, Scigalla P, Linderkamp O, Duc G et al. The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very-low-birth-weight infants, European Multicentre Erythropoietin Study Group. N Engl J Med. 1994; 330(17): 1173-1178. PubMed | Google Scholar

  12. Feldman AG, Sokol RJ. Neonatal Cholestasis. Neoreviews. 2013; 14(2). PubMed | Google Scholar

  13. Rath MEA, Smits-Wintjens VEHJ, Oepkes D, Walther FJ, Lopriore E. Iron status in infants with alloimmune haemolytic disease in the first three months of life. Vox Sang. 2013; 105(4): 328-333. PubMed | Google Scholar

  14. Smits-Wintjens VEHJ, Rath MEA, Lindenburg ITM, Oepkes D, van Zwet EW et al. Cholestasis in Neonates with Red Cell Alloimmune Hemolytic Disease: Incidence, Risk Factors and Outcome. Neonatology. 2012; 101(4): 306-310. PubMed | Google Scholar

  15. Aygun C, Tekinalp G, Gurgey A. Increased fetal iron load in rhesus hemolytic disease. Pediatr Hematol Oncol. 2004; 21(4): 329-333. PubMed | Google Scholar

  16. Yalaz M, Bilgin BS, Köroglu OA, Ay Y, Arikan C et al. Desferrioxamine treatment of iron overload secondary to RH isoimmunization and intrauterine transfusion in a newborn infant. Eur J Pediatr. 2011; 170(11): 1457-1460. PubMed | Google Scholar

  17. Bennardello F, Coluzzi S, Curciarello G, Todros T, Villa S et al. Recommendations for the prevention and treatment of haemolytic disease of the foetus and newborn. Blood Transfus. 2015; 13(1): 109-134. PubMed | Google Scholar